NASP is the only national association representing all specialty pharmacy industry stakeholders, amplifying our member’s collective voices through a multi-pronged, coordinated effort designed to educate, advocate, and affect positive change with congressional and administrative policy makers, elected officials, key congressional staffers, aligned pharmacy, and healthcare and patient advocacy associations.
Engage with NASP membership voices through a coordinated effort to train, deploy and release NASP members as public speakers, authors of editorials, participants in trade and public policy forums and frequent D.C- based face to face meetings with the influencers and powers to be that can facilitate change.
Resources for Members
- Receive the NASP Washington Update newsletter prepared for NASP members by Powers Pyles Sutter & Verville PC. This newsletter is sent to members to keep abreast of what is happening in Washington, to advise you of ways that you can get involved, and to provide you with updates on our grassroots advocacy efforts. Newsletters are also saved on our website and can be accessed by logging into the membership portal and clicking on the Washington Update tab.
- The Govpredict grassroots tool amplifies our collective voice as we work to develop actionable solutions to the issues that matter most. This easy to use web-based platform matches you to your respective elected officials and enables you to contact them directly.
Action for Members
- Join the Government Affairs Committee to identify issues that significantly impact NASP members and specialty pharmacy stakeholders, develop position statements and responses to educate and advocate on behalf of specialty pharmacy stakeholders. Learn more here.
- Apply to be a NASP Policy Council Member to focus on policy development and effectively articulate positions on policy matters NASP currently engages with and develop policy positions where needed. Council members are also responsible for identifying policy areas for engagement, so its activities are both proactive and reactive. All council members are selected from an application and review process.
Public Policy Advocacy
NASP continually collaborates with partnering organizations to amplify your voice and support all specialty pharmacy stakeholders though public policy advocacy and education.
View NASP’s Public Policy Advocacy efforts
NASP Resources
What is Specialty Pharmacy? NASP Definitions of Specialty Pharmacy and Specialty Medications
A Tangled Web: An Examination of the Drug Supply and Payment Chains
Announcements and Policies
- Lawmakers Warn RFK Jr. of Drug Price Talks’ Effect on Pharmacies
- NASP Message to Congress: You Must Do More to Protect Safe Senior Access to Specialty Medications and Medication Services and Protect Pharmacy Market Competition
- NASP Applauds President Trump for Efforts to Reduce Drug Pricing and Address Necessary PBM Reforms
- Pharmacy Organizations Press for Immediate PBM Reform as Health Subcommittee Holds Hearing
- Coalition letter on PBM reform.
- “An Examination of How Reining in PBMs Will Drive Competition and Lower Costs for Patients,” testimony By Sheila Arquette, President and CEO, NASP.
- NASP Submitted Comments: Response on MTF Agreements Feedback
- NASP Tells Congress and the Incoming Trump Administration: Pharmacies and Patients Can’t Continue to Wait for PBM Reform-Related Pharmacy Protections
- NASP Applauds Congressional Efforts to Address Anticompetitive Practices that Restrict Patient Access to Their Specialty Pharmacy
- Pharmacy Groups to “Key Vote” Continuing Resolution with Real PBM Reforms
- With United Voice, Pharmacy Urges Congress to Pass PBM Reforms in Joint Letter
- NASP Submits Written Testimony for Senate Finance Committee Hearing “Lower Health Care Costs for Americans: Understanding the Benefits of the Inflation Reduction Act.”
- Amid House Oversight Hearing, Pharmacy Organizations Issue United Call for Action on ‘Must-Pass’ PBM Reform Legislation
- NASP Comments On CMS’ Medicare Drug Price Negotiation Program Draft Guidance
- NASP Applauds the Senate Finance Chairman for Working to Address Unfair PBM Practices
- NASP Petitions SCOTUS to Reverse Lower Court Decision on Oklahoma Law
- HHS ANPRM on the IPI Model for Medicare Part B Drugs
- Medicare Program 2019 Policy and Technical Changes
- Announcement of Calendar Year 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter
- CMS Finalizes Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-F)
- 2019 Medicare Advantage and Part D Rate Announcement and Call Letter
- CMS Proposed Rule on Part D – November 16, 2017
- DIR Fees Increase Medicare Beneficiary and Medicare Program Costs for Specialty Drugs
- Any Willing Pharmacy (AWP) Changes Are Needed to Improve Beneficiary Access to Specialty Pharmacies
- Overview of AWP Provisions for 2017 Contract Year
- Overview of 2017 Direct and Indirect Remuneration Fees
